Daily Stock Analysis, ARRY, Array Biopharma Inc, priceseries

Array Biopharma Inc. Daily Stock Analysis
Stock Information
Open
8.75
Close
8.77
High
8.86
Low
8.65
Previous Close
8.78
Daily Price Gain
-0.01
YTD High
13.40
YTD High Date
Feb 10, 2017
YTD Low
6.73
YTD Low Date
May 9, 2017
YTD Price Change
0.21
YTD Gain
2.45%
52 Week High
13.40
52 Week High Date
Feb 10, 2017
52 Week Low
3.10
52 Week Low Date
Aug 25, 2016
52 Week Price Change
5.53
52 Week Gain
170.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 20. 2015
4.60
Feb 24. 2015
7.87
24 Trading Days
71.13%
Link
LONG
Mar 1. 2016
2.68
Mar 9. 2016
2.88
6 Trading Days
7.59%
Link
LONG
Apr 12. 2016
3.02
Apr 26. 2016
3.20
10 Trading Days
5.96%
Link
LONG
May 24. 2016
3.28
Jun 7. 2016
3.63
9 Trading Days
10.82%
Link
LONG
Jun 28. 2016
3.43
Jul 14. 2016
3.66
11 Trading Days
6.75%
Link
LONG
Nov 7. 2016
6.03
Dec 13. 2016
8.47
25 Trading Days
40.53%
Link
LONG
Jan 12. 2017
10.11
Jan 30. 2017
10.65
11 Trading Days
5.31%
Link
Company Information
Stock Symbol
ARRY
Exchange
NasdaqGM
Company URL
http://www.arraybiopharma.com
Company Phone
3033816600
CEO
Ron Squarer
Headquarters
Colorado
Business Address
3200 WALNUT STREET, BOULDER, CO 80301
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001100412
About

Array BioPharma, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, ONT-380 (ARRY-380), ARRY-797, Ipatasertib, Motolimod, Danoprevir, ARRy-614, GDC-0994, and LOXO-101. Its drugs focuses on the treatment of cancer and inflammatory diseases. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Description

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company's Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.